| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Fifteen healthy women participated in a study to determine the effect of multiple doses of troglitazone on the pharmacokinetics of Ortho-Novum 1/35 (35 micrograms ethinyl estradiol [EE] and 1 mg norethindrone [NE]). Participants received three cycles (21 days each of active drug followed by 7 days without medication) of Ortho-Novum. During the third cycle, participants also received troglitazone 600 mg qd for 22 days. Pharmacokinetic profiles of EE and NE were determined on day 21 of the second and third cycles. Progesterone and sex hormone binding globulin (SHBG) levels were also measured. Troglitazone decreased EE Cmax and AUC(0-24) by 32% and 29%, respectively. Likewise, troglitazone decreased NE Cmax and AUC(0-24) by 31% and 30%, respectively. Plasma SHBG concentrations increased from 113 nmol/L during cycle 2 to 220 nmol/L during cycle 3. Troglitazone reduced plasma unbound AUC for NE by 49%. Serum progesterone levels were lower than 1.5 ng/mL on all occasions. Thus, coadministration of troglitazone and Ortho-Novum decreases the systemic exposure to EE and NE. A higher dose of oral contraceptive or an alternate method of contraception should be considered for patients treated with troglitazone.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Schwartz, T. Hunt, W. B. Smith, P. Wong, P. Larson, T. Crumley, A. Mehta, K. Gottesdiener, and N. Agrawal The Effect of Etoricoxib on the Pharmacokinetics of Oral Contraceptives in Healthy Participants J. Clin. Pharmacol., July 1, 2009; 49(7): 807 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Oesterheld, K. Cozza, and N. B. Sandson Oral Contraceptives Psychosomatics, April 1, 2008; 49(2): 168 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Ripp, J. B. Mills, O. A. Fahmi, K. A. Trevena, J. L. Liras, T. S. Maurer, and S. M. de Morais Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction Drug Metab. Dispos., October 1, 2006; 34(10): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Dimaraki and C. A. Jaffe Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3113 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Khan, J. V. St. Peter, and J. L. Xue A Prospective, Randomized Comparison of the Metabolic Effects of Pioglitazone or Rosiglitazone in Patients With Type 2 Diabetes Who Were Previously Treated With Troglitazone Diabetes Care, April 1, 2002; 25(4): 708 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Morita, Y. Oki, T. Ito, H. Ohishi, S. Suzuki, and H. Nakamura Administration of Troglitazone, but Not Pioglitazone, Reduces Insulin Resistance Caused by Short-Term Dexamethasone (DXM) Treatment by Accelerating the Metabolism of DXM Diabetes Care, April 1, 2001; 24(4): 788 - 789. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
